Literature DB >> 21454633

Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.

Jonathan H Fox1, Teal Connor, Megan Stiles, Jibrin Kama, Zhen Lu, Kathryn Dorsey, Gregory Lieberman, Gregory Liebermann, Ellen Sapp, Robert A Cherny, Mary Banks, Irene Volitakis, Marian DiFiglia, Oksana Berezovska, Ashley I Bush, Steven M Hersch.   

Abstract

Huntington disease (HD) is a progressive neurodegenerative disorder caused by expression of polyglutamine-expanded mutant huntingtin protein (mhtt). Most evidence indicates that soluble mhtt species, rather than insoluble aggregates, are the important mediators of HD pathogenesis. However, the differential roles of soluble monomeric and oligomeric mhtt species in HD and the mechanisms of oligomer formation are not yet understood. We have shown previously that copper interacts with and oxidizes the polyglutamine-containing N171 fragment of huntingtin. In this study we report that oxidation-dependent oligomers of huntingtin form spontaneously in cell and mouse HD models. Levels of these species are modulated by copper, hydrogen peroxide, and glutathione. Mutagenesis of all cysteine residues within N171 blocks the formation of these oligomers. In cells, levels of oligomerization-blocked mutant N171 were decreased compared with native N171. We further show that a subset of the oligomerization-blocked form of glutamine-expanded N171 huntingtin is rapidly depleted from the soluble pool compared with "native " mutant N171. Taken together, our data indicate that huntingtin is subject to specific oxidations that are involved in the formation of stable oligomers and that also delay removal from the soluble pool. These findings show that inhibiting formation of oxidation-dependent huntingtin oligomers, or promoting their dissolution, may have protective effects in HD by decreasing the burden of soluble mutant huntingtin.
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454633      PMCID: PMC3093904          DOI: 10.1074/jbc.M110.199448

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

2.  Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease.

Authors:  M B Bogdanov; O A Andreassen; A Dedeoglu; R J Ferrante; M F Beal
Journal:  J Neurochem       Date:  2001-12       Impact factor: 5.372

3.  Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism.

Authors:  Ma Alba Sorolla; Ma José Rodríguez-Colman; Jordi Tamarit; Zaira Ortega; José J Lucas; Isidre Ferrer; Joaquim Ros; Elisa Cabiscol
Journal:  Free Radic Biol Med       Date:  2010-08-15       Impact factor: 7.376

4.  Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid.

Authors:  Kap-Seok Yang; Sang Won Kang; Hyun Ae Woo; Sung Chul Hwang; Ho Zoon Chae; Kanghwa Kim; Sue Goo Rhee
Journal:  J Biol Chem       Date:  2002-08-02       Impact factor: 5.157

5.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

Authors:  Ivelisse Sánchez; Christian Mahlke; Junying Yuan
Journal:  Nature       Date:  2003-01-23       Impact factor: 49.962

6.  Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Liliana B Menalled; Jessica D Sison; Ioannis Dragatsis; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Comp Neurol       Date:  2003-10-06       Impact factor: 3.215

7.  Transglutaminase cross-links in intranuclear inclusions in Huntington disease.

Authors:  Gina M Zainelli; Christopher A Ross; Juan C Troncoso; Nancy A Muma
Journal:  J Neuropathol Exp Neurol       Date:  2003-01       Impact factor: 3.685

8.  Oxygen-induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS.

Authors:  Yoshiaki Furukawa; Andrew S Torres; Thomas V O'Halloran
Journal:  EMBO J       Date:  2004-06-24       Impact factor: 11.598

9.  Protein disulfide bond formation in the cytoplasm during oxidative stress.

Authors:  Robert C Cumming; Nancy L Andon; Paul A Haynes; Minkyu Park; Wolfgang H Fischer; David Schubert
Journal:  J Biol Chem       Date:  2004-03-18       Impact factor: 5.157

10.  Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.

Authors:  Daryl A Bosco; Gerardo Morfini; N Murat Karabacak; Yuyu Song; Francois Gros-Louis; Piera Pasinelli; Holly Goolsby; Benjamin A Fontaine; Nathan Lemay; Diane McKenna-Yasek; Matthew P Frosch; Jeffrey N Agar; Jean-Pierre Julien; Scott T Brady; Robert H Brown
Journal:  Nat Neurosci       Date:  2010-10-17       Impact factor: 24.884

View more
  24 in total

1.  Harnessing Redox Cross-Reactivity To Profile Distinct Cysteine Modifications.

Authors:  Jaimeen D Majmudar; Aaron M Konopko; Kristin J Labby; Christopher T M B Tom; John E Crellin; Ashesh Prakash; Brent R Martin
Journal:  J Am Chem Soc       Date:  2016-02-05       Impact factor: 15.419

Review 2.  Oxidation as an important factor of protein damage: Implications for Maillard reaction.

Authors:  L Trnkova; J Drsata; I Bousova
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

Review 3.  The choreography of neuroinflammation in Huntington's disease.

Authors:  Andrea Crotti; Christopher K Glass
Journal:  Trends Immunol       Date:  2015-05-20       Impact factor: 16.687

Review 4.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

5.  Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

Authors:  H Diana Rosas; Y Iris Chen; Gheorghe Doros; David H Salat; Nan-kuei Chen; Ken K Kwong; Ashley Bush; Jonathan Fox; Steven M Hersch
Journal:  Arch Neurol       Date:  2012-07

6.  Post-aggregation oxidation of mutant huntingtin controls the interactions between aggregates.

Authors:  Yasushi Mitomi; Takao Nomura; Masaru Kurosawa; Nobuyuki Nukina; Yoshiaki Furukawa
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

7.  Conservation of oxidative protein stabilization in an insect homologue of parkinsonism-associated protein DJ-1.

Authors:  Jiusheng Lin; Janani Prahlad; Mark A Wilson
Journal:  Biochemistry       Date:  2012-04-24       Impact factor: 3.162

8.  HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Authors:  Miriam Moscovitch-Lopatin; Rachel E Goodman; Shirley Eberly; James J Ritch; H Diana Rosas; Samantha Matson; Wayne Matson; David Oakes; Anne B Young; Ira Shoulson; Steven M Hersch
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

9.  Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding.

Authors:  Guiran Xiao; Qiangwang Fan; Xiaoxi Wang; Bing Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

10.  Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain.

Authors:  Panagiotis Mastorakos; Clark Zhang; Sneha Berry; Yumin Oh; Seulki Lee; Charles G Eberhart; Graeme F Woodworth; Jung Soo Suk; Justin Hanes
Journal:  Adv Healthc Mater       Date:  2015-03-11       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.